Novo Nordisk manufacturing facility, and clients, hit by FDA action
Regulator classifies former Catalent site as ‘official action indicated’, impacting biotech clients such as Regeneron.
List view / Grid view
Regulator classifies former Catalent site as ‘official action indicated’, impacting biotech clients such as Regeneron.
Gains US-based operations with its new Phoenix, Arizona injectable drug product manufacturing and packaging site.
The investment will cover CMO collaborations and a new manufacturing and quality hub in Hyderabad.
He joins the US company with over two decades of experience in pharma operations, supply chain and manufacturing.
This update includes sterile manufacturing, bio-manufacturing, cell line development and radiopharmaceuticals.
Contract development and manufacturing services will be provided as Rezon Bio from Poland, with the biosimilars company operating from Switzerland.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
Contracts to use a facility at Fujifilm’s North Carolina site as part of moves to onshore its manufacturing.
The German pharma company’s BioXcellence arm will supply the drug substance for AnGes’ peripheral arterial disease treatment Collategene.
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
The CDMO’s new site will support its work in cell and gene therapy.
The deal between the two European CDMOs expands Ofichem’s Nordic biotech footprint and drug substance capabilities.
After their recent webinar, European Pharmaceutical Review’s Head of Content Ian Betteridge spoke with the team at Adragos Pharma to discuss the role of a CDMO and their importance in the fill and finish sector.
EPR Issue 2 includes articles on the impact of tariffs on the pharmaceutical supply chain, advances in bioprocessing, manufacturing and more.
The partnership will provide biotech companies with accelerated access to clinical development capabilities, including drug development and analytical services.